The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

According to US secondary stroke prevention guidelines, patients with ESUS should not be treated with anticoagulants or ...

A triple advantage can be achieved by shifting Mexicans' current diet toward that of the recommended Healthy and Sustainable ...

World Patient Safety Day provides an occasion to spread awareness of the medication errors that can result from products that ...

While the new Shield blood test may motivate more people to get screened for colorectal cancer, it also comes with downsides, ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...

PFAS are causing significant harm to the environment, people, pets, and wildlife, but it's not clear that proposed solutions ...

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.